The Association of the British Pharmaceutical Industry, a trade group representing UK drug makers, announced that it has reached a voluntary deal with the UK government that involves capping the growth of sales of brand-name drugs to the National Health Service at 2% per year in exchange for faster product launches and speedier appraisals by the National Institute for Clinical Excellence (NICE).
The Association of the British Pharmaceutical Industry (ABPI), a trade group representing UK drug makers, announced that it has reached a voluntary deal with the UK government that involves capping the growth of sales of brand-name drugs to the National Health Service (NHS) at 2% per year in exchange for faster product launches and speedier appraisals by the National Institute for Clinical Excellence (NICE).
Under the Branded Medicines Pricing and Access deal, which is expected to take effect in January 2019 once it has been agreed to in full, the cap applies to the sales of all branded drugs to the NHS, and pharmaceutical companies will repay the NHS for spending that exceeds that limit. According to ABPI, the cap could deliver approximately £930 million (approximately $1.2 billion) in savings in 2019.
In exchange for the 2% cap, the Department of Health and Social Care (DHSC) has agreed that drug makers will receive faster appraisals from NICE, the nation’s health technology assessment body, which could lead to launches expedited by up to 6 months. Drugs recommended by NICE must be funded by the NHS, and the deal, says ABPI, will mean that all new medicines will be receive a NICE appraisal.
According to the DHSC, companies that offer the best-value new medicines will also have “opportunities for greater commercial flexibility.” Price increases of drugs will continue to require DHSC’s approval, however.
ABPI adds that the deal will simplify price controls for pharma; brand-name drug makers that do not participate in voluntary industry—government agreements on drug pricing are currently required to pay to pay the government 7.8% of their sales of products to the NHS. Notably, in August 2018, the UK government proposed bringing biosimilar drugs under these price controls, prompting criticism from the biosimilars industry. Neither ABPI nor DHSC specified whether the simplified price controls under the newly formed deal would encompass biosimilars.
While ABPI has pointed to the 2% maximum as a boon for the NHS, currently, growth in spending on branded drugs is capped at 1.9% for 2018 under the Pharmaceutical Price Regulation Scheme, an agreement that expires at the end of this year and that will be supplanted by the new agreement.
Furthermore, announcement of the agreement comes just as the NHS is poised to slash its yearly spending on brand-name Humira, the costliest drug to the health system, after the arrival of biosimilar adalimumab; this week, the NHS announced that spending on adalimumab would drop by £300 million (approximately $386 million) as it implements biosimilars of the high-cost drug.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.
BioRationality: Time to Get Rid of PBMs if Biosimilars Are to Succeed
July 15th 2024Sarfaraz K. Niazi, PhD, discusses the challenges with pharmacy benefit managers (PBMs) that plague the biosimilar industry and new legislation that attempts to reform their practices and encourage biosimilar adoption.